Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial for PB-119 in Healthy Subjects (Phase I)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female volunteers, ages: between 18-45;~* Body weight： female \>= 45kg, male \>=50kg, BMI \>=19-24kg/m2~* Physical examination, blood routine, urine routine, liver and kidney function and related laboratory tests are normal or slightly abnormal but not clinically significant;~* Read, agree, and sign the informed consent;~* Be able to communicate with the investigator and finish the study according to the protocol.~Exclusion Criteria （anyone or more of the following):~* Allergic to the API or excipients used (citric acid, mannitol, Meta-Cresol);~* Experiencing clinically significant disease or surgery within 4 weeks before the study;~* Clinically significant disease history in systems including cardiovascular system, endocrine system, neutral system, immunology system, psychiatry，metabolic disorder;~* Disease history of gastrointestinal tract, liver, and kidney (for example, the Partial resection surgery in GI tract, liver, or kidney);~* Fever history within 3 days of the screening;~* Clinical significant abnormality found in laboratory tests (blood, urine routine test) within 2 weeks before study;~* ECG or vital signs is clinically significant abnormality as judged by the Investigator( systolic blood pressure \<90mmHg or ≥140mmHg; diastolic blood pressure\<60mmHg or ≥90mmHg; heart rate \<50bpm or \>100bpm);~* Antibody test for HIV, BsAg, C hepatitis, or Microspironema pallidum positive;~* Alcoholics or drink frequently within 6 months of trial (more than 14 unit of alcohol, in which 1 unit is 360mL beers, or 45 ml wine with 40% alcohol content, or 150mL port wine;~* Addicted to cigarette, tea, coffee or drugs;~* Have specific requirement for diets (or allergic to any food);~* Have been administered in the past 2 weeks with any drug (such as antibiotics, anticoagulant, diuretics) that might interfere the PK profile of drug/drug candidate to be used in this study;~* Participated in any clinical trial in the past 3 months;~* Donated blood of more than 360 ml in the past 3 months;~* Plan to be pregnant herself or his spouse in the next 6 months;~* Females administered with any oral contraceptive 30 days before the study or during the study;~* Females dosed with long acting estrogen or progestin (injections or implant) 6 months before the study or during the study;~* Females at childbearing age that had unprotected intercourse 14 days before the study or will have during the study;~* Female who is pregnant or nursing;~* Anybody who might not be able to complete the study, or considered not appropriate by the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Exenatide analogue, Injection (Type: EXPERIMENTAL): PB-119 will be administered once weekly subcutaneously at dosage of 2μg、5μg、10μg、25μg、50μg、100μg、200μg or 400μg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete